sorafenib has been researched along with Carcinoma, Medullary in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 8 (72.73) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abelleira, E; Bueno, F; Jerkovich, F; Pitoia, F; Schmidt, A | 1 |
| Abouzied, Mel-D; Aklabi, S; Duaiji, N; Hammami, MM; Mutairi, G; Qattan, N; Sous, MW | 1 |
| Moretti, S; Puxeddu, E; Romagnoli, S; Voce, P | 1 |
| Arbogast, D; Collamore, M; Hall, NC; Kloos, RT; Knopp, MV; Lam, ET; Liang, J; Moley, JF; Prior, TW; Ringel, MD; Saji, M; Sammet, S; Shah, MH; Snyder, PJ; Vasko, VV; Villalona-Calero, MA; Wakely, PE; Wei, L; Wright, JJ | 1 |
| Fagin, JA; Pfister, DG; Tuttle, RM | 1 |
| Dralle, H; Machens, A | 1 |
| Couto, JP; Martins, TC; Prazeres, H; Rodrigues, F; Soares, P; Sobrinho-Simões, M; Torres, J; Trovisco, V; Vinagre, J | 1 |
| Aller, S; Gosiengfiao, Y; Morgan, E; Popescu, A; Rao, S | 1 |
| Meyer, P; Missana, A | 1 |
| Fagin, JA | 1 |
| Chintala, L; El Naggar, AK; Gagel, R; Hong, D; Kurzrock, R; Wright, J; Ye, L | 1 |
2 review(s) available for sorafenib and Carcinoma, Medullary
| Article | Year |
|---|---|
Targeted molecular therapies in thyroid carcinoma.
Topics: Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Medullary; Carcinoma, Papillary; Humans; Imidazoles; Indazoles; Indoles; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thyroid Neoplasms | 2009 |
How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Medullary; Carcinoma, Papillary; Humans; Mutation; Niacinamide; Oncogenes; Phenylurea Compounds; Phosphotransferases; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Thyroid Neoplasms | 2004 |
2 trial(s) available for sorafenib and Carcinoma, Medullary
| Article | Year |
|---|---|
Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.
Topics: Administration, Oral; Adult; Aged; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Medullary; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Thyroid Neoplasms; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; United States; Young Adult | 2010 |
In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.
Topics: Adult; Aged; Animals; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Benzenesulfonates; Blotting, Western; Carcinoma, Medullary; Case-Control Studies; Cell Transformation, Neoplastic; Cells, Cultured; Female; Germ-Line Mutation; Humans; Kidney; Luciferases; Male; Mice; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutagenesis, Site-Directed; Niacinamide; NIH 3T3 Cells; Pedigree; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-ret; Pyridines; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Thyroid Neoplasms; Transcription Factor 4; Transcription Factors; Young Adult | 2011 |
7 other study(ies) available for sorafenib and Carcinoma, Medullary
| Article | Year |
|---|---|
Rare complications of multikinase inhibitor treatment.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Carcinoma, Medullary; Female; Follow-Up Studies; Heart Failure; Humans; Intestinal Perforation; Kaplan-Meier Estimate; Male; Middle Aged; Oophoritis; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Quinazolines; Quinolines; Retrospective Studies; Risk Factors; Sorafenib; Thrombocytopenia; Thyroid Neoplasms; Time Factors; Young Adult | 2018 |
Case report of severe Cushing's syndrome in medullary thyroid cancer complicated by functional diabetes insipidus, aortic dissection, jejunal intussusception, and paraneoplastic dysautonomia: remission with sorafenib without reduction in cortisol concentr
Topics: Adult; Antineoplastic Agents; Aortic Aneurysm; Aortic Dissection; Carcinoma, Medullary; Cushing Syndrome; Diabetes Insipidus; Fatal Outcome; Humans; Hydrocortisone; Intussusception; Jejunal Diseases; Male; Niacinamide; Paraneoplastic Polyneuropathy; Phenylurea Compounds; Primary Dysautonomias; Sorafenib; Thyroid Neoplasms | 2015 |
Harvesting the low-hanging fruit: kinase inhibitors for therapy of advanced medullary and nonmedullary thyroid cancer.
Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Medullary; Carcinoma, Papillary; Humans; Indoles; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Thyroid Neoplasms | 2010 |
Parenchymal versus nonparenchymal target lesion response in clinical trials for metastatic medullary thyroid cancer.
Topics: Administration, Oral; Benzenesulfonates; Biomarkers, Tumor; Calcitonin; Carcinoembryonic Antigen; Carcinoma, Medullary; Clinical Trials, Phase II as Topic; Disease-Free Survival; Humans; Lymph Node Excision; Lymphatic Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Thyroid Neoplasms; Treatment Outcome | 2010 |
Transient partial response to sorafenib treatment in an adolescent patient with MEN2B syndrome and end-stage medullary thyroid carcinoma.
Topics: Adolescent; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Medullary; Female; Humans; Multiple Endocrine Neoplasia Type 2b; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Thyroid Neoplasms | 2012 |
[Endocrinology].
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Benzenesulfonates; Carcinoma; Carcinoma, Medullary; Clinical Trials as Topic; Endocrine Gland Neoplasms; Endocrinology; Humans; Niacinamide; Phenylurea Compounds; Pituitary ACTH Hypersecretion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Receptors, Somatostatin; Somatostatin; Sorafenib; Thyroid Neoplasms; Treatment Outcome | 2012 |
Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib.
Topics: Adult; Amino Acid Sequence; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Medullary; Cell Line, Tumor; Exons; Humans; Male; Molecular Sequence Data; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Pyridines; Quinolones; Sorafenib; Thyroid Neoplasms | 2008 |